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Background: Delayed cerebral ischemia and cerebral vasospasm 
remain the leading causes of poor outcome in survivors of 
aneurysmal subarachnoid hemorrhage. Refractory cerebral 
vasospasms can be treated with endovascular vasodilator therapy, 
which can either be performed in conscious sedation or general 
anesthesia. The aim of this study is to compare the effect of the 
anesthesia modality on long-term clinical outcomes in patients 
undergoing endovascular vasodilator therapy due to cerebral 
vasospasm and hypoperfusion. 
Methods: Modified Rankin Scale (mRS) scores were retrospectively 
analyzed at time of discharge from the hospital and six months after 
aneurysmal subarachnoid hemorrhage. Additionally, National 
Institutes of Health Stroke Scale (NIHSS) was assessed 24 hours 
before, immediately before, immediately after, and 24 hours after 
endovascular vasodilator therapy, and at discharge and six months. 
Interventional parameters such as duration of intervention, choice 
and dosage of vasodilator and number of arteries treated were also 
recorded. 
Results: A total of 98 patients were included in this analysis and 
separated into patients who had interventions in conscious sedation, 
general anesthesia and a mix of both. Neither mRS at discharge nor at 
six months showed a significant difference for functionally 
independent outcomes (mRS 0-2) between groups. NIHSS before 
endovascular vasodilator therapy was significantly higher in patients 
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receiving interventions in general anesthesia but did not differ 
anymore between groups six months after the initial bleed. 
Conclusion: This study did not observe a difference in outcome 
whether patients underwent endovascular vasodilator therapy in 
general anesthesia or conscious sedation for refractory cerebral 
vasospasms. Hence, the choice should be made for each patient 
individually.
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Introduction
Cerebral vasospasms (CVS) and delayed cerebral ischemia still remain among the leading causes ofmorbidity andmortality
in survivors of aneurysmal subarachnoid hemorrhage (aSAH). Up to 40% of aSAHpatients experience symptomatic CVS,
resulting in disability in up to 50% thereof.1 CVS, a narrowing of cerebral arteries thought to be caused by blood breakdown
products, mostly develop between 5 to 14 days after aSAH.2 So far, there is no therapy known, which was shown in
randomized trials to improve cerebral perfusion and thus to avoid brain ischemia and infarction in symptomatic patients.
Commonly used rescue treatments for symptomatic CVS include induced hypertension, and in refractory CVS angioplasty
or intra-arterial application of vasodilators, e.g. nimodipine or papaverine.1,3,4 Both have been shown in case series to
improve neurological outcome in said patients.5–7
In recent years, several studies investigated the best method of anesthesia for endovascular treatment in acute ischemic
stroke.8–20While initially in mostly retrospective studies, data showed conscious sedation (CS) to be superior,8,9 a recent
meta-analysis showed no significant difference in outcomes for CS and general anesthesia (GA)17 if only randomized
controlled trials were considered.15,16,18 To the best of our knowledge, no studies comparing CS and GA in endovascular
treatments for refractory CVS after aSAH have been performed.
The aim of this study is to compare six-month outcomes for choice of sedation in patients treated with endovascular
vasodilators for CVS after aSAH.
Methods
This is a single-center retrospective case-control study analyzing clinical outcomes in patients with symptomatic CVS
after aSAH treated with endovascular vasodilators at the University Hospital Bern, Bern, Switzerland.
Study design
The University Hospital Bern conducts a prospective database for patients treated with aSAH. This database was
retrospectively searched for patients hospitalized between September 2011 and October 2019. Only patients aged >18
and <85 years were included. Inclusion criteria were: 1) aSAH of all severities (World Federation of Neurosurgeons
(WFNS) score I–V), 2) secured aneurysm either by endovascular or surgical treatment, 3) refractory CVS treated by intra-
arterial admission of either nimodipine and/or papaverine. Exclusion criteria were: 1) incomplete data, 2) loss of follow
up, 3) continuous intra-arterial nimodipine treatment, 4) re-rupture of aneurysm during the hospital stay.
Patients were divided into three treatment groups: patients who underwent treatment with endovascular vasodilators in
CS only (“CS”), in GA only (“GA”), or patients who received intra-arterial treatments in CS and GA (“both”). Choice of
anesthesia modality was made by the treating physician on an individual basis. However, according to institutional
guidelines, GA was preferred in patients with impaired consciousness (GCS ≤ 8) or insufficient swallowing.
Data collection
All data was acquired from patient records and the institutional electronic Patient DataManagement System (CentricityTM
Critical Care,General ElectricCompany,GEHealthcare,United States ofAmerica).Vital signs are automatically recorded
and the bedside team additionally enters clinical scores and administered drugs into the system.
The primary endpoint of this study was functional outcome at six months, analyzed by the modified Rankin Scale
(mRS). Secondary outcome parameters included mRS at discharge and National Institutes of Health Stroke Scale
(NIHSS) assessed 24 hours before the (first) intra-arterial vasodilator treatment (t1), directly before (t2), directly after
(last) treatment (t3), 24 hours after (last) treatment (t4) and consecutively at discharge from the hospital (t5) and after six
months (t6). Further parameters consisted of interventional parameters such as duration of intervention, choice of
vasodilator (nimodipine or papaverine), number of treated arteries and vasodilator dosage.
Patient characteristics such as age, sex, aneurysm location and treatment andBarrowNeurological Institute (BNI), Fisher,
Hunt & Hess and WFNS scores were obtained from institutional patient records.
REVISED Amendments from Version 1
To address key issues in the reviewer comments, text was added to the methods section of the paper clarifying how the
choice of anesthesia was made in each patient. Additionally, WFNS, Hunt & Hess, BNI and Fisher Scores were statistically
analyzed. The corresponding p-values were added to Table 1.
Any further responses from the reviewers can be found at the end of the article
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Statistical analysis
The statistical analysis was performed using SPSS Statistics 21.0 (IBM, Armonk, NY, USA). The Shapiro-Wilk
normality test was used to test for normal distribution.
Univariate Analysis of Variance (ANOVA) test was used to compare “CS”, “GA” and “both” groups for differences in
age as well as BNI, Fisher, Hunt & Hess and WFNS scores. Differences in sex and aneurysm treatment were explored
with Pearson Chi Squared analysis.
For mRS at discharge and six months, outcomes were divided in functionally independent (mRS 0-2) and functionally
dependent (mRS 3-6). A Chi Squared test was used to test for significant group differences between CS, GA and both.
An additional subgroup analysis was performed using a Chi Squared test with “CS” and “GA” groups divided into single
versusmultiple interventions, resulting in five groups (“single CS”, “single GA”, “multiple CS”, “multiple GA”, “both”).
For the analysis of NIHSS, a 3 6 analysis of variance (ANOVA) for repeatedmeasureswith post hocBonferroni correction
for multiple comparisons was conducted. The factors were (i) treatment (“CS”, “GA” and “both”) and (ii) time (t1 – t6).
Interventional parameters were analyzed for each intervention separately and therefore compared between those
performed in CS and GA. For the duration of the intervention, a Welch's two sample t-test was performed. The choice
of vasodilator was analyzed by Pearson Chi Squared test. Vasodilator dosage as well as number of treated arteries were
analyzed with an independent samples t-test.
Data are presented as mean with standard deviation (SD) in brackets and in figures as mean with +1 SD as error bars.
A p-value of p < 0.05 was considered statistically significant.
Ethics statement
This study was carried out in accordance with the recommendations of the local ethics committee (Kantonale
Ethikkommission Bern, Switzerland). All subjects gave written general consent in accordance with the Declaration of
Helsinki. The protocol was approved by the local ethics committee (Kantonale Ethikkommission Bern, Switzerland).
Results
In total, 109 patients with refractory CVS treated by intra-arterial admission of either nimodipine and/or papaverine between
September 2011 andOctober 2019 at theUniversityHospital Bern, Bern, Switzerlandwere included.Of those, 11 patients had
to be excluded. Reasons for exclusion were incomplete data (n = 2), re-rupture of aneurysm during the hospital stay (n = 2),
continuous intra-arterial nimodipine treatment (n = 1) and loss of follow-up at six months (n = 6). The final study population
consisted of 98 patients, 23 patients in the “CS” group, 53 patients in the “GA” group and 22 patients in the “both” group. In the
“CS” group, 16 patients received a single intervention (“single CS”) and seven patients received up to five interventions
(“multipleCS”). In theGAgroup, 26 patients received one intervention (“singleGA”) and27 patients received 2-10 treatments
(“multiple GA”). As per definition, all patients in the “both” group received more than one and up to 10 interventions.
Patient characteristics
Table 1 shows patient characteristics of the three anesthesia groups. Overall mean age was 54.7 years (range 24-81). All
groups showed higher percentages of female patients. Age, sex, aneurysm treatment modality did not significantly differ
between the three groups.
Primary outcome
mRS at six months is displayed in Figure 1a. There was a tendency for a slightly higher percentage of functionally independent
patients (mRS0-2) in the “CS” group (78.3%) at sixmonths.However, this difference did not prove to be statistically significant
(p = 0.109). The subgroup analysis comparing single and multiple intra-arterial interventions separately for each anesthesia
modality is displayed in Table 2. This analysis also revealed no significant difference in functional outcome at six months
between “single CS”, “single GA”, “multiple CS”, “multiple GA” and “both” groups (p = 0.089).
Secondary outcomes
Figure 1b shows mRS at discharge from hospital. This analysis displays no significant difference between “CS”, “GA”
and “both” groups (p = 0.056). The subgroup analysis for single and multiple interventions separately also revealed no
statistical significance (p = 0.156), as listed in Table 2.
The NIHSS time course analysis is presented in Figure 2. ANOVA for repeated measures displayed a significant
interaction of “time*treatment” (p = 0.008) and of “time” (p < 0.001). Post-hoc analysis revealed that significant group
differences only occur when comparing “GA” to the two other groups. All of these significant differences were between t1
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Table 1. Patient characteristics.
CS GA Both Total p-value
Number of patients 23 53 22 98
Mean age (years, range) 57.0 (32 – 74) 54.0 (24 – 81) 53.7 (36 – 72) 54.7 (24 – 81) 0.550#
Sex 0.219+
Female 20 (87%) 40 (75%) 21 (91%) 80 (82%)
Male 3 (13%) 13 (25%) 2 (9%) 18 (18%)
Admission WFNS Score 0.023*#
I 12 (52%) 15 (28%) 8 (36%) 35 (36%)
II 1 (4%) 7 (13%) 9 (41%) 17 (17%)
III 3 (13%) 5 (9%) 1 (5%) 9 (9%)
IV 4 (17%) 14 (26%) 4 (18%) 22 (22%)
V 3 (13%) 12 (23%) 0 (0%) 15 (15%)
Hunt & Hess Score 0.023*#
1 3 (13%) 6 (11%) 4 (18%) 13 (13%)
2 11 (48%) 16 (30%) 13 (59%) 40 (40%)
3 3 (13%) 7 (13%) 2 (9%) 12 (12%)
4 0 (0%) 7 (13%) 1 (5%) 8 (8%)
5 6 (26%) 17 (32%) 2 (9%) 25 (26%)
BNI Score 0.999#
1 0 (0%) 0 (0%) 0 (0%) 0 (0%)
2 7 (30%) 15 (28%) 8 (36%) 30 (31%)
3 8 (35%) 22 (42%) 7 (32%) 37 (38%)
4 5 (22%) 8 (15%) 2 (9%) 15 (15%)
5 3 (13%) 8 (15%) 5 (23%) 16 (16%)
Fisher score 0.675#
1 0 (0%) 0 (0%) 0 (0%) 0 (0%)
2 2 (9%) 0 (0%) 0 (0%) 2 (2%)
3 14 (61%) 38 (72%) 18 (82%) 70 (71%)
4 7 (30%) 15 (28%) 4 (18%) 26 (27%)
Aneurysm location
Choroideal artery 0 (0%) 1 (2%) 0 (0%) 1 (1%)
ACA 1 (4%) 0 0%) 0 (0%) 1 (1%)
ACOM 9 (39%) 18 (34%) 5 (23%) 32 (33%)
Basilar 2 (9%) 4 (7%) 2 (9%) 8 (8%)
ICA 1 (4%) 6 (11%) 1 (5%) 8 (8%)
MCA 5 (21%) 9 (17%) 6 (27%) 20 (20%)
PCA 1 (4%) 0 (0%) 0 (0%) 1 (1%)
PCOM 1 (4%) 10 (19%) 7 (32%) 18 (18%)
A.pericallosa (A2) 2 (9%) 0 (0%) 0 (0%) 2 (2%)
PICA 0 (0%) 3 (6%) 0 (0%) 3 (3%)
Superior cerebellar artery 1 (4%) 1 (2%) 0 (0%) 2 (2%)
Vertebral 0 (0%) 1 (2%) 1 (5%) 2 (2%)
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Table 1. Continued
CS GA Both Total p-value
Aneurysm treatment 0.916+
Clipping 5 (21%) 10 (19%) 4 (18%) 19 (19%)
Coiling 18 (78%) 42 (79%) 18 (82%) 78 (80%)
Flow diverter 0 (0%) 1 (2%) 0 (0%) 1 (1%)
Where not stated otherwise, values represent the number of patients with their respective percentages in brackets. WFNS: World




Figure 1. Distribution ofmodified Rankin Scale (mRS) categories according to anesthesiamodality (Conscious
Sedation = “CS”, General Anesthesia = “GA” and Conscious Sedation as well as General Anesthesia = “both”).
Numbers represent the percentages for each mRS category per group. a) “CS”, “GA” and “both” at six-month follow
up. b) “CS”, “GA” and “both” at discharge from hospital.














11 (68.8%) 7 (100%) 16 (61.5%) 12 (44.4%) 14 (63.6%) 0.089+
mRS
3-6





9 (56.3%) 4 (57.1%) 9 (34.6%) 6 (22.2%) 7 (31.8%) 0.156+
mRS
3-6
7 (43.8%) 3 (42.9%) 17 (65.4%) 21 (77.8%) 15 (68.2%)
Values represent the number of patients with their respective percentages in brackets. mRS: modified Rankin Scale; CS: conscious
sedation; GA: general anesthesia.
+Chi-squared test.
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and t5, meaning between 24 hours before (first) intervention and discharge from the hospital. At the six-month follow up
appointment, “CS”, “GA” and “both” did not differ significantly regarding NIHSS.
Interventional parameters
Interventional parameters are displayed in Table 3. Overall, a total of 237 intra-arterial vasodilator treatments were
performed, 65 of which were performed in CS and 172 in GA. Mean duration of intervention was significantly longer if
performed in GA (p = 0.002). A total of four interventions had to be excluded from further analysis because of missing
Figure 2. Bar graphdepictingNational Institutes ofHealth Stroke Scale (NIHSS) scores of the three anesthesia
groups. Patients were treated in conscious sedation (“CS”), general anesthesia (“GA”) or a combination of both
(“both”). Each bar represents a different group. Each cluster represents a different time point. Time points are
24 hours before (first) intra-arterial vasodilator intervention (t1), immediately before (t2), immediately after (t3),
24 hours after (last) intervention (t4), at discharge from the hospital (t5) and at six-month follow up (t6). Data are
presented asmean +1 StandardDeviation (SD) as error bars. Significant inter-groupdifferences are highlightedwith
asterisks. One asterisk represents p < 0.05, two asterisks represent p < 0.01 and three asterisks represent p < 0.001.
Table 3. Interventional parameters for intra-arterial vasodilator treatments.
CS GA p-value Total
Number of interventions 65 172 237
Duration of intervention
(min.)




Nimodipine 59 147 206
Papaverine 3 15 18
Nimodipine and papaverine 2 7 9
Medication dosage (mg)
Nimodipine 4.8 (1.7) 4.8 (1.7) 0.928# 4.8 (1.7)
Papaverine 200.0 (69) 224.2 (100) 0.696# 212.1 (94)








Number of treated arteries 1.8 (0.6) 2 (0.8) 0.057# 1.9 (0.8)
Where not stated otherwise, values represent the means with the standard deviation in brackets. CS: conscious sedation; GA: general
anesthesia.
+Welch’s two sample t-test.
xChi-squared test.
#Independent samples t-test.
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data about medication (n = 3) and number of treated arteries (n = 1). Neither choice and dosage of intra-arterial
vasodilator, nor number of treated arteries showed significant differences between groups.
Discussion
This retrospective study found no significant differences in functionally independent outcomes (mRS 0-2) six months after
aSAH in patients who were treated with intra-arterial vasodilators in CS, GA or a combination of both. While NIHSS was
significantly higher in patients undergoing endovascular therapy inGAcompared to patients of the “CS”or “both”group in the
timewindow 24 hours before intervention up to discharge from the hospital, this differencewas no longer found at sixmonths.
To the best of our knowledge, the effect of anesthesia modality (CS versus GA) on functional outcome has not yet
been studied for intra-arterial admission of either nimodipine and/or papaverine in patients with refractory CVS after
aSAH. Albeit, there have been several research papers published regarding anesthesia in aneurysm treatment.21–23
Most articles describe both CS and GA to be generally safe for treatment of unruptured aneurysms or aSAHwith no clear
recommendation for either one.
Additionally, multiple studies have had similar research questions in relation to the choice of anesthesia during
endovascular therapy of acute ischemic stroke. Abou-Chebl et al. (2010) showed in their analysis of the “North American
SOLITAIRE Stent-Retriever Acute Stroke” (NASA) registry, that patients treated in GA experienced poorer neurologic
outcome at 90 days and highermortality rates than patients treated in CS.8 Berkhemer et al. (2016) reported similar results
in a post-hoc analysis of a prospective trial.15 Correspondingly, a recent analysis of the “Endovascular Therapy Following
Imaging Evaluation for Ischemic Stroke 3” (DEFUSE 3) trial by Powers et al. (2019) showed higher rates of functional
independence (mRS 0-2) and a lower NIHSS score at 24 hours for patients treated in CS. At discharge they did not find a
statistically significant difference in NIHSS scores anymore.11
In contrast, most recent randomized controlled trials found a non-inferiority of GA when compared to CS. Hendén et al.
(2017) reported no difference in outcome at three months or NIHSS after 24 hours in their Anesthesia During Stroke
(AnStroke) Trial.16 Schönenberger et al. (2016) and Simonsen et al. (2018) report, that GA produced better 3-month
outcomes, with the former even finding this result to be significant.18,19 Finally, a recent meta-analysis determined no
significant difference between GA and CS if only randomized controlled trials were considered.17
Our results are in line with these recent randomized controlled trials published for endovascular treatment in acute
ischemic stroke. Similar to Schönenberger et al. (2016), Hendén et al. (2017), Simonsen et al. (2018) and Kim et al.
(2019), we also found no significant difference in functional independency (mRS 0-2) at discharge or six months.16–19
Similar considerations regarding choice of anesthesia hold true in intra-arterial vasodilator therapy after aSAH and
treatment for acute ischemic stroke alike. Disadvantages of GA may be a delay in treatment, hemodynamic changes and
complications associated with intubation such as an increased risk for pneumonia.8 Disadvantages of CS may be
procedural discomfort for patients, more difficult interventions because of patients’movements, emergency conversion
to GA or increased risk for aspiration.8 Many of the conceived disadvantages of GA have also been analyzed in
prospective studies concerning ischemic stroke treatment. For example, Berkhemer et al. (2016) as well as Hendén et al.
(2017) found no treatment delay in the GA group.15,16 Schönenberger et al. (2016) reported no difference in feasibility,
safety and intra-interventional complication between the groups.18 They did however discover more postprocedural
complications after GA such as delayed extubation and pneumonia. Different authors mention the possibility of blood
pressure drops and decreased cerebral blood flow as possible additional complications of GA, which could potentially
worsen outcomes because of an increase of the ischemic area.15 Others argue that GA on its own has a neuroprotective
effect by lowering the neuronal oxygen need.24,25 Overall, the similar functional outcome in our study as well as in the
above cited studies in ischemic stroke suggest that these factors are of minor relevance.
Themajor limitations of this study are its retrospective design and the single-center approach. A potential bias could lie in
the choice of sedation for treatment. Even before intra-arterial vasodilator treatment, patients who would go on to receive
treatments in GA showed significantly higher NIHSS scores when compared to the “CS” and “both” groups. This
indicates that patients in clinically and neurologically worse conditions were more likely to be treated in GA. However,
this bias was not reflected in our results, as we did not find a significant difference in mRS scores between the anesthesia
groups at discharge or at six months and also no significant difference in NIHSS scores at six months. The “GA” group
were therefore in an initially worse state but still managed to reach similar outcomes in the long-term clinical course. This
suggests to an even greater degree, that GA will not negatively affect long term outcome in these patients.
Furthermore, some subgroups consisted of a small number of patients. The results of this study will have to be replicated
by a larger prospective trial in the future.
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Conclusion
Our preliminary results indicate that choice of anesthesia method does not negatively affect six-month outcome in aSAH
patients who undergo intra-arterial vasodilator treatment for CVS. Treating physicians should therefore decide between
CS and GA individually based on patient characteristics and circumstances.
Data availability
Underlying data
Dryad: FunctionalOutcome after intraarterial vasodilator therapy inCSvsGA, https://doi.org/10.5061/dryad.g4f4qrfq5.26
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public
domain dedication).
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This is a retrospective study. 
 
How were the NIHSS extracted from the patients files? Is NIHSS performed routinely? If the 
patient was already intubated, how was NIHSS evaluated? 
 
While aneurysma location as well as Fisher score seem to be similar, WFNS/ H&H seem to differ 
between CS + GA (e.g. 52% vs 28% WFNS 1). Is there a statistical difference? If so, how do you 
explain the lack of association thereof with the outcome? 
 
Patients with high WFNS + Fisher scores commonly remain intubated in case of unsuccessful 
sedation-reduction trial. How many patients were already under GA before intra-arterial 
vasodilatation. Is there difference in delay between non-intubated patients to CS or GA intra-
arterial vasodilatation? 
 
When mRS at 6 months is compared between CS and GA only (excluding both) irrespective of if 
they received a singular or multiple CS/GA statistical significance is reached. How do you explain 
this finding?
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Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
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If applicable, is the statistical analysis and its interpretation appropriate?
Partly
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In our institution, NIHSS is routinely assessed in stroke patients at least once a day as well 
as before and after interventions. In intubated patients, the NIHSS is determined after 
depth of sedation is decreased as much as clinically possible. The NIHSS assessment is 
performed according to the recommendation of the National Institute of Neurological 
Disorders and Stroke (
https://www.ninds.nih.gov/sites/default/files/NIH_Stroke_Scale_Booklet.pdf). Most notably, 
intubated patients get a default score of 1 for verbally assessed categories such as 
orientation if they are unable to speak or write. Additionally, aphasia is assessed through 
writing. Dysarthria is not assessable in the intubated patient. 
 
The p-values for WFNS, Hunt&Hess, BNI and Fisher scores were added to Table 1. Only the 
WFNS and Hunt&Hess scores differed significantly between the groups. However, as it has 
been shown in two earlier publications cited below, WFNS 5 scores at admission are often 
over-estimated due to accompanying factors e.g. early seizures. In addition, if factors such 
as intubation, ventilation, sedation, muscle relaxation or insufficient pain stimuli inhibit said 
motor response, the WFNS grading can be over-estimated while the outcome is not 
necessarily impacted. Similar effects can alter Hunt&Hess gradings. In contrast the 
radiologically determined scores (BNI and Fisher) are not influenced by the above factors, 
which can at least partially explain that these two sores are not significantly different while 
the clinical ones are. (Fung et al., 2016; Fung et al., 2015). 
 
In addition, more severely ill patients corresponding to patients with higher WFNS and 
Hunt&Hess scores are more probable to undergo intra-arterial vasodilatator therapy in 
general anesthesia (see also below.) 
 
Twenty-two patients were already ventilated before the first intra-arterial vasodilator 
treatment (this corresponds to 37% of all patients who were intubated for the first intra-
arterial vasodilator treatment). Unfortunately, due to the retrospective study design, the 
additional delay of intra-arterial vasodilatation therapy due to intubation was not assessable 
within the obtained documentation. 
 
Considering only mRS at 6 months and reducing the analysis to patients who were only 
treated with one modality (CS or GA), the outcome differed significantly between the two 
groups (Fisher exact p = 0.044). 
 
In our opinion this analysis has to be interpreted with caution as the number of patients 
undergoing intra-arterial vasodilator treatment in CS who showed an unfavorable outcome 
is very small (n = 5). Furthermore, if the above mentioned patients who remained intubated 
after the initial bleeding are excluded from this analysis, the result is no longer statistically 
significant (p = 1.000). This indicates that the difference in outcome of this additional 
analysis is probably mainly due to the initial disease severity and not due to the anesthesia 
modality chosen for intra-arterial vasodilator treatment.  
Competing Interests: No competing interests were disclosed.
 
Page 12 of 14
F1000Research 2021, 10:417 Last updated: 09 AUG 2021
Reviewer Report 13 July 2021
https://doi.org/10.5256/f1000research.55588.r88125
© 2021 Roelz R. This is an open access peer review report distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Roland Roelz  
Department of Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, 
University of Freiburg, Freiburg, Germany 
This is an interesting preliminary study on the anesthesia modality for endovascular rescue 
therapies in patients with aneurysmal subarachnoid hemorrhage (aSAH). This single-center 
retrospective study included 98 aSAH patients (admitted in an 8-year period) selected for 
endovascular vasospasm therapy. Circa half of these patients were treated in general anesthesia, 
25% were treated in conscious sedation and 25% had multiple interventions and both anesthesia 
modalities were applied. No differences in outcome (6-months mRS) were observed between 
these groups. 
 
Carefully interpreted and fully aware of the limitations associated with the study design and data 
collection, this study may indicate towards safety and non-inferiority of both general anesthesia 
and conscious sedation for endovascular interventions after aSAH. These findings are in keeping 
with the pertinent literature on anesthesiologic management of endovascular interventions for 
stroke. 
 
I thank the authors for sharing their first experience with conscious sedation as an alternative to 
general anesthesia for endovascular vasospasm therapy. I encourage investigating the clinical 
algorithm that triggers the choice for either method. 50% of patients treated in general anesthesia 
had admission WFNS grades 4 or 5 (i.e. poor grade aSAH) compared to 30% of patients selected 
for conscious sedation. A fact that may very well explain the presumed tendency towards better 
outcomes of the latter group. The rate of delayed infarction should have been reported. Given that 
safety of conscious sedation seems to apply to endovascular vasospasm therapy, future studies 
are warranted. They should follow a prospective and randomized design. Potential benefits of 
conscious sedation (i.e. more rapid return to neurological assessability after intervention, less 
complications of mechanical ventilation etc.) might be of high clinical relevance and could improve 
outcome of patients who develop clinical vasospasm.
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The following text was added to the methods section of the manuscript: “Choice of 
anesthesia modality was made by the treating physician on an individual basis. However, 
according to institutional guidelines, GA was preferred in patients with impaired 
consciousness (GCS <=8) or insufficient swallowing.”  
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